Conference Call with Alkem Laboratories Management and Analysts on Q1FY23 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals firm Alkem Laboratories Announced Q1FY23 Result : Total Revenue from Operations was Rs 25,764 million, YoY decline of 5.7% India sales were Rs 17,815 million, YoY decline of 6.7% International sales were Rs 7,604 million, YoY decline of 3.8% Earnings before Interest, Tax, Depreciation and Amortization (EBITDA) was Rs 2,032 million, resulting in EBITDA margin of 7.9% vs. 21.7% in Q1FY21. EBITDA declined by 65.7% YoY R&D; expenses for the quarter was Rs 1,320 million, or 5.1% of total revenue from operations compared to Rs 1,183 million in Q1FY22 at 4.3% of total revenue from operations Profit before tax (PBT) was Rs 1,519 million, a decline of 72.7% compared to Q1FY22 Net Profit (after Minority Interest) was Rs 1,276 million, YoY decline of 72.7% Commenting on the results, Sandeep Singh, Managing Director, Alkem said, “We are starting the new fiscal year on a positive note, with yet another market beating performance in domestic market adjusting for huge base of last year [CAGR of 13.4%, Q1FY20-Q1FY23]. However, headwinds from price erosion in US market and inflationary environment has impacted margins for the quarter. As we move ahead, we remain focused on our journey of expanding margins through productivity improvement and various cost optimization initiatives across the organization. Our biosimilar franchise is shaping up well and we are looking forward to some exciting launches going ahead.” Result PDF
Pharmaceuticals firm Alkem Laboratories declares Q4FY22 result: Key highlights of Q4FY22 financial performance: Total Revenue from Operations was Rs 24,839 million, YoY growth of 13.3%. India sales were Rs 17,187 million, YoY growth of 16.7% International sales were Rs 7,411 million, YoY growth of 7.3% Earnings before Interest, Tax, Depreciation and Amortization (EBITDA) was Rs 3,372 million, resulting in EBITDA margin of 13.6% vs. 13.3% in Q4FY21. EBITDA grew by 15.8% YoY R&D; expenses for the quarter was Rs 1,634 million, or 6.6% of total revenue from operations compared to Rs 1,408 million in Q4FY21 at 6.4% of total revenue from operations Profit before tax (PBT) was Rs 2,427 million, a decline of 6.0% compared to Q4FY21. Exceptional Item of Rs 150 million debit was on account of fair value of an investment Net Profit (after Minority Interest) was Rs 1,076 million, YoY decline of 55.2%. Commenting on the results, Sandeep Singh, Managing Director, Alkem said, "FY22 was a mixed bag for the Company as our India business did well helped by COVID-19 tailwinds, while our US business faced significant pricing pressure. We forayed in the Indian respiratory segment with the launch of Pulmocare division which received an encouraging response. Our biotech subsidiary Enzene also made good progress with product launches in India and signing multiple product out-licensing deals. Going forward, while we are positive about our growth prospects given the levers we have built over the years, navigating the inflationary pressures of high raw material prices and increased freight rates, would be a key challenge for the Company." Result PDF
Conference Call with Alkem Laboratories Management and Analysts on Q4FY22 Performance and Outlook. Listen to the full earnings transcript.